Simultaneous suppression of the MAP kinase and NF-κB pathways provides a robust therapeutic potential for thyroid cancer

Highlights • We examined simultaneous targeting of two pathways, the MAP kinase and NF-κB pathways. • We used two FDA approved drugs, AZD6244 and Bortezomib. • Dual drug treatment caused significant apoptosis in vitro. • Dual drug treatment caused the inhibition of cell growth and migration in vitro...

Full description

Saved in:
Bibliographic Details
Published in:Cancer letters 2015-11, Vol.368 (1), p.46-53
Main Authors: Tsumagari, Koji, Abd Elmageed, Zakaria Y, Sholl, Andrew B, Friedlander, Paul, Abdraboh, Mohamed, Xing, Mingzhao, Boulares, A. Hamid, Kandil, Emad
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Apoptosis
Apoptosis - drug effects
AZD6244
Benzimidazoles - administration & dosage
Bortezomib
Bortezomib - administration & dosage
Cell cycle
Cell Cycle - drug effects
Cell growth
Cell Line, Tumor
Cell migration
Cell Movement - drug effects
Cell proliferation
Cell Proliferation - drug effects
Clinical trials
Dephosphorylation
Dose-Response Relationship, Drug
Drug resistance
Growth rate
Hematology, Oncology and Palliative Medicine
Humans
Inhibitor drugs
Iodine
Kinases
Male
MAP kinase
MAPK
Medical research
Metastasis
Mice, Inbred BALB C
Mice, Nude
Mitogen-Activated Protein Kinases - antagonists & inhibitors
Mitogen-Activated Protein Kinases - metabolism
Mortality
Mutation
Neoplasm Invasiveness
NF-kappa B - antagonists & inhibitors
NF-kappa B - metabolism
NF-κB
NF-κB protein
Phosphorylation
Proto-Oncogene Proteins B-raf - genetics
Signal Transduction - drug effects
Thyroid cancer
Thyroid Neoplasms - drug therapy
Thyroid Neoplasms - enzymology
Thyroid Neoplasms - genetics
Thyroid Neoplasms - pathology
Time Factors
Tumor Burden
Tumorigenesis
Tumors
Xenograft Model Antitumor Assays
Xenografts
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • We examined simultaneous targeting of two pathways, the MAP kinase and NF-κB pathways. • We used two FDA approved drugs, AZD6244 and Bortezomib. • Dual drug treatment caused significant apoptosis in vitro. • Dual drug treatment caused the inhibition of cell growth and migration in vitro. • Dual drug treatment in the xenograft model caused a significant reduction in tumor size.
ISSN:0304-3835
1872-7980
DOI:10.1016/j.canlet.2015.07.011